engleski

Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma

Targeted therapy with a BRAF inhibitor and a MEK inhibitor (BRAFi/MEKi) is a well-established treatment option for patients with BRAF-mutated advanced stage melanoma. In disease progression, sequencing between immune checkpoint inhibitors and BRAFi/ MEKi is a common approach. Recently, the question of efficacy, tolerability and possible toxicity of sequential therapy has been raised. We report here the first case of concomitant development of Stevens- Johnson syndrome and isolated severe anaemia in a patient undergoing treatment with vemurafenib plus cobimetinib following pembrolizumab therapy for advanced stage BRAF-mutated melanoma.

anemia ; cobimetinib ; melanoma ; Stevens-Johnson syndrome ; pembrolizumab ; vemurafenib

nije evidentirano